What is the recommended induction and maintenance therapy for proliferative lupus nephritis (class III/IV)?

Recommended Treatment for Proliferative Lupus Nephritis (Class III/IV)

For induction therapy of active Class III/IV lupus nephritis, treat with glucocorticoids plus mycophenolic acid analogs (MPAA) as first-line, with alternatives including low-dose intravenous cyclophosphamide, or triple therapy with belimumab plus MPAA/cyclophosphamide, or MPAA plus a calcineurin inhibitor when kidney function is preserved. 1

Induction (Initial) Therapy

The 2024 KDIGO guidelines provide four equally recommended first-line options 1:

1. Mycophenolic acid analogs (MPAA) - Target dose 2-3 g/day of mycophenolate mofetil or equivalent MPA dose
2. Low-dose intravenous cyclophosphamide - 500 mg every 2 weeks for 6 doses
3. Belimumab + MPAA or low-dose cyclophosphamide - Triple immunosuppression
4. MPAA + calcineurin inhibitor - When eGFR >45 mL/min/1.73 m²

Glucocorticoid Regimens

Glucocorticoids are combined with all induction regimens. The 2024 KDIGO guidelines now recommend reduced-dose schemes 1:

• Methylprednisolone pulses: 0.25-0.5 g/day for up to 3 days initially
• Oral prednisone: Start at 0.5-0.6 mg/kg/day (max 40 mg) for weeks 0-2
• Rapid taper: Down to 2.5 mg/day by week 13-14 in the reduced-dose scheme
• Target <5 mg/day by 6 months

This represents a significant shift from older high-dose schemes (0.8-1.0 mg/kg/day) to minimize glucocorticoid toxicity while maintaining efficacy 1.

Choosing Between Induction Options

Select MPAA-based regimens for:

• Patients at high risk of infertility 1
• Those with prior cyclophosphamide exposure 1
• General first-line use given comparable efficacy to cyclophosphamide with better tolerability 2

Select cyclophosphamide for:

• Patients with adherence concerns (IV route ensures compliance) 1
• Severe disease with adverse prognostic factors (crescents/necrosis in >25% of glomeruli, nephritic sediment with GFR 25-80 mL/min) - consider high-dose regimen 2

Select MPAA + calcineurin inhibitor for:

• Preserved kidney function (eGFR >45 mL/min/1.73 m²) with nephrotic-range proteinuria 1
• Extensive podocyte injury 1
• Patients intolerant to standard-dose MPAA or cyclophosphamide 1

Select belimumab triple therapy for:

• Repeated kidney flares 1
• High risk for progression to kidney failure with severe CKD 1

Maintenance (Subsequent) Therapy

After completing induction therapy (typically 3-6 months), transition to MPAA for maintenance therapy. 1

Maintenance Regimen Details

• Mycophenolate mofetil: 750-1000 mg twice daily 1
• Mycophenolic acid: 540-720 mg twice daily 1
• Duration: Minimum 36 months total (induction + maintenance combined) 1
• Glucocorticoids: Taper to lowest possible dose, ideally <7.5 mg/day 1, 2; discontinuation can be considered after ≥12 months of complete clinical response 1

Alternative Maintenance Options

Azathioprine is an acceptable alternative for patients who 1:

• Cannot tolerate MPAA
• Lack access to MPAA
• Are planning pregnancy

Continue triple therapy (belimumab or CNI-based) if used during induction 1

Treatment Response Targets

Timeline for Response Assessment 1, 2

• 3 months: Evidence of improvement in proteinuria with GFR normalization/stabilization
• 6 months: At least 50% reduction in proteinuria (partial clinical response)
• 12 months: Proteinuria <0.5-0.7 g/24 hours with normal/near-normal GFR (complete clinical response)

Important caveat: For patients with baseline nephrotic-range proteinuria, extend these timeframes by 6-12 months before considering treatment failure 2.

When to Switch Therapy

If response targets are not met at the designated timepoints, consider switching induction regimens or adding rituximab for refractory disease 1.

Critical Adjunctive Measures

All patients require 1:

• Hydroxychloroquine with ophthalmologic monitoring
• RAAS blockade (ACE inhibitors/ARBs) for proteinuria
• Pneumocystis jirovecii prophylaxis during intensive immunosuppression
• Bone protection: Calcium, vitamin D, bisphosphonates when appropriate
• Fertility preservation counseling: GnRH agonists or gamete cryopreservation before cyclophosphamide
• Infection screening: HBV, HCV, HIV, tuberculosis
• Minimize lifetime cyclophosphamide exposure to <36 g total

Evidence Quality Considerations

The 2024 KDIGO guidelines 1 represent the most current and comprehensive recommendations, superseding the 2019 EULAR/ERA-EDTA guidelines 2. Key updates include the addition of belimumab and CNI-based triple therapy as first-line options, and emphasis on reduced glucocorticoid dosing. Network meta-analyses 3 and Cochrane reviews 4 support MPAA and CNI combinations showing superior or equivalent efficacy to cyclophosphamide with improved safety profiles, particularly regarding alopecia and ovarian failure.